In short. Hydration and skin quality for the best-studied injected class, and much less for the rest of a category that shares only a name.
Key points
- The distinction is not pedantic.
- A category defined by placement has no mechanism, no indication and no study in common, so a strong result for its best-studied member is a fact about that member.
- Presenting it as a fact about the category is the single most common overstatement in this subject.
The evidence in this category is concentrated in one member of it, and the whole of what is established belongs to that member rather than to the group.
Hydration and skin quality, for one class
The injected hyaluronic acid class has the longest record and the clearest support. The substance is well characterised and its behaviour in tissue is understood, the endpoints of hydration and skin quality are measurable, and the microdroplet technique is what the evidence describes. That is a real body of work and it is a body of work about one product class, not about the category.
Placement matters, and it is part of the evidence
Depth, spacing and quantity determine what a booster does, and the same product placed differently is a different treatment with a different risk profile. That is established as a principle and it is why the technique belongs in any honest account: a claim that rests on the product alone has described half of what determines the result, and the half it has left out is the one the operator controls.
Established for a class is not established for a category
The distinction is not pedantic. A category defined by placement has no mechanism, no indication and no study in common, so a strong result for its best-studied member is a fact about that member. Presenting it as a fact about the category is the single most common overstatement in this subject.
The effect is temporary, and that is established
A booster does not prevent the processes that produced whatever is being treated, and the effect fades. Maintaining it means repeating the treatment, which means repeating the risks. That is a fact about the category as a whole, it applies to every member of it, and it belongs in the plan from the beginning rather than emerging after a course has been completed.
The rest of the group
Polynucleotides are emerging, with evidence that is real and younger. Injected vitamin mixtures have no comparable evidence and usually no approved claim as a skin treatment. Topical products are a different class regulated by a different route. None of those positions is a finding about whether the products work; each is a statement about how much is known, and a reader is entitled to know which of them applies to what is being offered.
The evidence, by member of the group
- Established: hydration and skin quality for the injected hyaluronic acid class.
- Emerging: polynucleotides, real evidence, newer and thinner, market-dependent.
- Not supported as a class: injected vitamin mixtures, and topicals claiming equivalence.
Those three lines are what the category looks like when its members are kept apart, which is the only way it can be read.
Frequently asked questions
What is established for skin boosters?
Hydration and skin quality for the injected hyaluronic acid class, which is the best-studied member with the longest record. The endpoints are measurable, the substance is well characterised, and microdroplet placement is the technique the evidence is about. Everything established in this category belongs to that class.
What about polynucleotides?
Emerging. The evidence is real, newer and narrower than the hyaluronic acid record, and availability varies by market. A reader may meet confident claims and the accurate description is that these products are promising and less well documented than the substances they are often compared with.
Does a course produce lasting change?
No. The effect is temporary and maintaining it requires repeating the treatment, which is established for the category. A study reporting a change at a defined point after a course is reporting a temporary result rather than a durable one, and a course described as producing lasting change has described a maintenance programme as an outcome.
Risks & Limitations
- Skin booster is a category defined by how a substance is placed, so its members are not interchangeable and evidence does not transfer between them.
- The established evidence belongs to the injected hyaluronic acid class: hydration and skin quality, with microdroplet placement.
- Approval is per product and per market, and a product approved in one jurisdiction may not be approved in another.
- The effect is temporary, and maintaining it means repeating the treatment and repeating the risks.
- A booster does not add volume or lift tissue that has descended, and no injectable is approved to lift.
When to Seek Care
- Severe pain, or skin that becomes dusky, mottled or pale after an injection — seek emergency care immediately.
- A change in vision, or pain around the eye, after any injection to the face — seek emergency care immediately.
- A fever with spreading redness, or a lump that is painful and enlarging, is assessed by a clinician rather than watched.
- A rash, or nodules that appear or persist after an injection, are assessed by a clinician rather than treated further.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — approved injectable products and their labelled indications
- National Medical Products Administration (NMPA, China) — approved products and their indications
- European Medicines Agency (EMA) and national regulators — injectable product assessments
- Cochrane Library — systematic reviews of injectable skin treatments
- Chinese Medical Association Plastic Surgery Branch — clinical guidance
This page is a review of published evidence and regulation, not medical advice, and it does not cite individual studies. It is not a booking page and it does not recommend a product or treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.